The FDA approved TMS treatment in 2008 after studies showed that TMS therapy can safely and effectively reduce symptoms of depression. It helped people who didn’t get better with antidepressants. This approval was a big step forward in mental health care. TMS works without the need for daily medication or surgery. Since then, it’s grown into a trusted, science-backed treatment for people with hard-to-treat depression.
What Led to the FDA’s 2008 Approval of TMS for Depression?
The FDA’s 2008 approval of transcranial magnetic stimulation (TMS) for major depressive disorder (MDD) was not based on theory. It was grounded in hard data from one of the largest neuromodulation trials at the time. The pivotal study, led by O’Reardon et al., was a rigorous, double-blind, sham-controlled, multisite randomized controlled trial. In this important trial, 301 patients with treatment-resistant depression took part. These were people who didn’t get better after trying at least one antidepressant drug. They were randomly split into two groups. One group received active TMS treatment. The other group received a sham, or placebo, version of TMS.
TMS targeted the left dorsolateral prefrontal cortex, an area repeatedly implicated in depression based on neuroimaging studies. Patients received TMS five days a week for 4 to 6 weeks, using parameters of 10 Hz stimulation, 120% of motor threshold, and 3,000 pulses per session. The results showed that active TMS significantly outperformed the sham group across multiple depression rating scales, including the Montgomery-Asberg Depression Rating Scale (MADRS) and the 17- and 24-item Hamilton Depression Rating Scales (HAMD-17, HAMD-24).
By week 6, remission rates were about twice as high in the active TMS group compared to the sham group. Furthermore, adverse effects were minimal, with only 4.5% of patients discontinuing due to side effects, most commonly mild scalp discomfort. Importantly, there were no systemic side effects, no weight gain, no sexual dysfunction, no cognitive impairment – issues that are often seen with antidepressant medications(1).
This clinical trial met the FDA’s requirements for demonstrating both efficacy and safety in a population with limited options. In October 2008, the FDA cleared Neuronetics’ NeuroStar TMS Therapy System, the first non-invasive device of its kind, for adults with treatment-resistant depression.
How Has TMS Therapy Evolved Since Its Initial Approval?
Initially, a full course of treatment required 30 to 36 sessions over 6–7 weeks, each lasting nearly an hour. This time commitment limited accessibility for many patients. However, innovations in stimulation protocols have shortened treatment times significantly.
One of the biggest breakthroughs was the development of intermittent theta burst stimulation, or iTBS. It’s a faster version of traditional repetitive TMS (rTMS). iTBS sends bursts of magnetic pulses at a higher frequency. A full session takes about 3 minutes instead of 37. In 2018, the FDA approved iTBS (using the MagVenture device) as a new standard for depression treatment, with the same results in much less time.
Another major evolution has been the rise of Accelerated TMS (aTMS) protocols. Researchers at Stanford, for example, developed the Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT) protocol, which condenses what used to be six weeks of treatment into five days by delivering multiple iTBS sessions per day (2). SAINT achieved 79% remission rates in patients with severe, treatment-resistant depression, far surpassing traditional timelines and outcomes.
TMS has also expanded beyond depression. The FDA has since approved TMS devices for:
- Obsessive-compulsive disorder (OCD) in 2018
- Migraine with aura in 2013
- Smoking cessation in 2020
- Anxious depression in 2021
New coil designs, like the H-coil, allow TMS to reach deeper areas of the brain. This helps treat more difficult cases of depression and other conditions. Today, TMS is not seen as experimental anymore. It’s a well-established and widely accepted treatment.
Why Is TMS Considered a Valuable Option for Treatment-Resistant Depression?
Some people with depression don’t improve after trying one or more antidepressant medications. For them, TMS can offer a different kind of relief, one that doesn’t involve changing the body’s overall chemistry. Instead, TMS uses focused magnetic pulses to stimulate areas of the brain involved in mood regulation.
Unlike medication, TMS works only where it’s needed, without affecting the entire body. That means it avoids many common side effects like weight gain, sedation, or emotional numbness. Most people tolerate the treatment well, with only minor side effects like mild scalp discomfort during or after sessions.
What also makes TMS valuable is how it targets the biology of depression. Brain imaging studies have linked depression to underactivity in specific areas, especially the left dorsolateral prefrontal cortex. TMS is designed to re-activate those circuits, helping the brain form healthier activity patterns over time.
How Does the TMS Institute of Arizona Stand Out in Providing TMS Therapy?
The TMS Institute of Arizona is built around one thing: helping people with depression get real results through focused brain stimulation. TMS isn’t a side service here. It’s the core of what we do.
What makes our care different:
- Precise Targeting: We begin with a detailed review of each patient’s mental health and medical history. Every treatment plan starts by mapping the brain’s motor threshold to deliver stimulation exactly where it’s needed.
- Science-Backed Methods: We use rTMS, accelerated TMS (aTMS), and tDCS, based on each person’s symptoms and history, with protocols grounded in clinical research.
- Expert-Led Treatment: Our team includes board-certified physicians who have years of experience in neuromodulation. Progress is monitored closely and adjusted based on how the patient is responding.
- Steady, Hands-On Support: Each session is supervised by trained staff who know the process inside and out. Patients are never left to figure things out on their own.
- Care That Continues: For those who need it, we suggest preservation TMS right after treatment and maintenance sessions if symptoms return to help keep progress on track.
We’ve worked with people who felt stuck, worn out, or frustrated by medications that didn’t work. Many have come through our doors and walked away with a better quality of life. This is what we’re known for, and we take it seriously.
Contact the TMS Institute of Arizona Today!
If depression keeps getting in the way, it may be time for something different. The TMS Institute of Arizona uses research-backed brain stimulation to help people feel better, without medication. We use proven methods, precise targeting, and years of clinical experience to guide every session.
We focus on what works, and we stick with you through the process. If you’re ready to break the cycle, contact us. Let’s talk about what’s really possible.
References
- O’Reardon, J. P., Solvason, H. B., Janicak, P. G., Sampson, S., Isenberg, K. E., Nahas, Z., McDonald, W. M., Avery, D., Fitzgerald, P. B., Loo, C., Demitrack, M. A., George, M. S., & Sackeim, H. A. (2007). Efficacy and Safety of Transcranial Magnetic Stimulation in the Acute Treatment of Major Depression: A Multisite Randomized Controlled Trial. Biological Psychiatry, 62(11), 1208–1216. https://doi.org/10.1016/j.biopsych.2007.01.018
- Cole, E. J., Stimpson, K. H., Bentzley, B. S., Merve Gulser, Cherian, K., Tischler, C., Nejad, R., Pankow, H., Choi, E., Aaron, H., Espil, F. M., Pannu, J., Xiao, X., Duvio, D., Solvason, H. B., Hawkins, J., Guerra, A., Jo, B., Raj, K. S., & Phillips, A. L. (2020). Stanford Accelerated Intelligent Neuromodulation Therapy for Treatment-Resistant Depression. American Journal of Psychiatry, 177(8), 716–726. https://doi.org/10.1176/appi.ajp.2019.19070720
